Suppr超能文献

人类丙型肝炎病毒感染中的移植相关自身免疫机制。

Transplant-associated autoimmune mechanisms in human hepatitis C virus infection.

作者信息

Zucker K, Roth D, Cirocco R, Mathew J, Carreno M, Fuller L, Karatzas T, Jin Y, Burke G, Nery J, Webb M, Tzakis A, Esquenazi V, Miller J

机构信息

Department of Surgery, University of Miami School of Medicine, Florida 33101, USA.

出版信息

J Clin Immunol. 1996 Jan;16(1):60-70. doi: 10.1007/BF01540974.

Abstract

In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.

摘要

为了确定对移植患者丙型肝炎病毒(HCV)感染和疾病发展至关重要的因素,我们研究了II类主要组织相容性复合体(MHC)抗原限制在病毒抗原呈递中的作用,以支持这种疾病与自身免疫发病机制相关的假说。这些供体与其HCV阴性受者之间组织相容性匹配程度越高,移植后受者发生HCV肝病(谷丙转氨酶升高)的倾向就越大。在长期血液透析患者和长期肾移植患者中,通过自体混合淋巴细胞反应(AMLR)的显著增强可识别HCV携带状态,但在伴有HCV相关肝硬化的终末期肝病患者中不存在AMLR,且在新肝移植后的头两年持续感染的这些患者中AMLR升高不明显。与未出现慢性肝病生化证据的肾移植患者相比,出现慢性肝病生化证据的肾移植患者自体反应性以及血清HCV滴度也有适度降低。这种情况在疾病过程中出现得较晚。仅在一部分HCV感染的肾移植患者的外周血单核细胞(PBMC)中可检测到HCV RNA,这些患者显示出明显更高的自体反应性。相比之下,尽管在原位肝移植后观察时间较早,但在所有接受检测的肝移植受者的PBMC中都发现了HCV RNA(即在新的或复发性疾病过程的早期)。通过用富集的可能处于免疫复合物中的HCV(pHCV-IC)预孵育未感染的实验室志愿者的刺激细胞(抗原呈递细胞,APC),可增强其AMLR。这种增强仅在HCV毒株与HLA DR血清型的特定组合中出现。此外,可产生对该病毒的HCV致敏T细胞,其显示出加速的激活动力学。从HCV阳性终末期患病肝脏中提取的肝浸润淋巴细胞对自体(HCV感染的)肝细胞的增殖和细胞毒性反应明显高于对来自HCV阴性肝脏的自体肝细胞反应的提取淋巴细胞。这些发现为HCV疾病进展过程中的动态自身免疫机制提供了证据,并可能有助于预测在器官移植受者疾病进展的不同阶段进行干预的效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验